Kit for the preparation of gallium Ga 68 gozetotide injection

FDA Drug Profile — ILLUCCIX

Drug Details

Generic Name
Kit for the preparation of gallium Ga 68 gozetotide injection
Brand Names
ILLUCCIX
Application Number
NDA214032
Sponsor
Telix Pharmaceuticals (US) Inc.
NDC Codes
1
Dosage Forms
KIT
Routes
INTRAVENOUS
Active Ingredients
N/A

Indications and Usage

1 INDICATIONS AND USAGE ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products ILLUCCIX, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products ( 1 )